As the Australian share market shows resilience with a +0.4% advance amidst global uncertainties, particularly contrasting Wall Street's downturn, investors are keenly observing how local factors such as potential interest rate changes influence trading sentiment. In this environment, companies with high insider ownership often attract attention for their perceived alignment of interests between management and shareholders, making them notable candidates for those seeking growth opportunities on the ASX.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Torque Metals (ASX:TOR) 18.3% 94.2% Titomic (ASX:TTT) 14.7% 82.9% Starpharma Holdings (ASX:SPL) 15.6% 91.8% SKS Technologies Group (ASX:SKS) 28.2% 31.7% Magnetic Resources (ASX:MAU) 33.6% 124.2% Image Resources (ASX:IMA) 20.4% 148.6% Forrestania Resources (ASX:FRS) 32.4% 102.3% Echo IQ (ASX:EIQ) 19.7% 108.7% Austral Resources Australia (ASX:AR1) 19.4% 38.8% Adveritas (ASX:AV1) 17.9% 109.9%

Click here to see the full list of 110 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Aurelia Metals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aurelia Metals Limited is involved in the exploration and production of mineral properties in Australia, with a market cap of A$431.82 million.

Operations: The company generates revenue from its mineral exploration and production activities in Australia.

Insider Ownership: 25.9%

Earnings Growth Forecast: 23.8% p.a.

Aurelia Metals shows promising growth potential with earnings forecasted to grow significantly at 23.8% annually, outpacing the Australian market. Its recent half-year results reflect a strong performance with sales reaching A$206.87 million and net income of A$22.59 million, indicating robust operational momentum. While trading well below its estimated fair value and expected to rise by 63.9%, insider ownership remains stable without substantial recent buying or selling activity, suggesting confidence in long-term prospects.

Dive into the specifics of Aurelia Metals here with our thorough growth forecast report. Our valuation report here indicates Aurelia Metals may be undervalued.ASX:AMI Ownership Breakdown as at Apr 2026

Regis Healthcare

Simply Wall St Growth Rating: ★★★★★☆

Overview: Regis Healthcare Limited provides residential aged care services in Australia and has a market cap of A$2.06 billion.

Operations: The company generates revenue of A$1.26 billion from residential aged care, home care, and retirement living services in Australia.

Insider Ownership: 38.6%

Story Continues

Earnings Growth Forecast: 22.7% p.a.

Regis Healthcare is positioned for growth, with earnings expected to rise by 22.7% annually, surpassing the Australian market's forecast. The company reported A$744.7 million in revenue for the recent half-year, though net income declined to A$13.44 million from A$24.4 million a year prior. Insider activity shows more buying than selling recently, albeit not in large volumes, indicating confidence amid strategic acquisitions and greenfield development plans supported by a robust balance sheet and undrawn debt facilities.

Delve into the full analysis future growth report here for a deeper understanding of Regis Healthcare. Our valuation report unveils the possibility Regis Healthcare's shares may be trading at a discount.ASX:REG Ownership Breakdown as at Apr 2026

Telix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$5.05 billion.

Operations: The company's revenue is derived from three primary segments: Therapeutics ($9.27 million), Precision Medicine ($621.93 million), and Manufacturing Solutions ($245.11 million).

Insider Ownership: 14.9%

Earnings Growth Forecast: 45.5% p.a.

Telix Pharmaceuticals is poised for growth, with revenue projected to increase by 14% annually, outpacing the Australian market. Despite a net loss of US$7.13 million in 2025, strategic collaborations, such as with Regeneron Pharmaceuticals and advancements in glioblastoma treatments like TLX101-Tx entering Phase 3 trials, bolster its potential. The company's strong insider ownership could reflect confidence in its innovative pipeline and expanding global presence through new regulatory approvals and strategic alliances.

Take a closer look at Telix Pharmaceuticals' potential here in our earnings growth report. Our expertly prepared valuation report Telix Pharmaceuticals implies its share price may be lower than expected.ASX:TLX Ownership Breakdown as at Apr 2026

Make It Happen

Discover the full array of 110 Fast Growing ASX Companies With High Insider Ownership right here. Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:AMI ASX:REG and ASX:TLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments